Citi, Stifel Bullish on Olema (OLMA) Despite COO Departure

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) is one of 15 stocks with the biggest hedge fund momentum, after gaining 28 hedge fund holders during the fourth quarter of 2025. On February 19, Citi analyst Yigal Nochomovitz maintained a Buy rating on Olema Pharmaceuticals Inc. (NASDAQ:OLMA) and set a price target of $60. Meanwhile, on February 11, Stifel initiated coverage of Olema Pharmaceuticals Inc. (NASDAQ:OLMA) with a Buy rating and $48 price target, saying that it conservatively modeled peak sales estimates of $3.1B in 2035 for lead asset palazestrant. The analyst added that endocrine therapy could be “a $20 billion plus global market opportunity with plenty of room for many big players.”

These analyst actions followed a January 30 announcement from Olema Pharmaceuticals Inc. (NASDAQ:OLMA) that Shane Kovacs, its Chief Operating Officer and Chief Financial Officer, had departed the company, effective the same day. The company stated that Kovacs is leaving to pursue new opportunities and will remain in a consulting role through August 1, 2026. The company also announced that Sean Bohen, Olema’s Chief Executive Officer, has assumed the responsibilities of principal financial officer on an interim basis until a successor is appointed.

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of next-generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies

READ NEXT: 13 Hot Stocks to Buy with the Highest Upside Potential and 10 Best High-Upside Materials Stocks to Buy

Disclosure: None.  Follow Insider Monkey on Google News.